These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 16203653)

  • 1. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
    Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S
    Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.
    Foidart JM
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
    Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R
    Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E; Skarabis H; Wuttke W; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
    Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yasmin: the reason why.
    Thorneycroft IH
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
    Fruzzetti F; Lazzarini V; Ricci C; Quirici B; Gambacciani M; Paoletti AM; Genazzani AR
    Contraception; 2007 Sep; 76(3):190-4. PubMed ID: 17707715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of drospirenone/estrogen combinations on bone metabolism.
    Christiansen C
    Climacteric; 2005 Oct; 8 Suppl 3():35-41. PubMed ID: 16203654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
    Foidart JM; Faustmann T
    Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.
    Dickerson V
    J Reprod Med; 2002 Nov; 47(11 Suppl):985-93. PubMed ID: 12497673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
    Sangthawan M; Taneepanichskul S
    Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.
    Endrikat J; Sandri M; Gerlinger C; Rübig A; Schmidt W; Fortier M
    Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):220-8. PubMed ID: 17763260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
    Palacios S; Foidart JM; Genazzani AR
    Maturitas; 2006 Nov; 55(4):297-307. PubMed ID: 16949774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yasmin--a new oral contraceptive, a new progestogen: the reasons why.
    Mansour D
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():9-16. PubMed ID: 11246601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.